NCT03586843View on ClinicalTrials.gov

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 29, 2018

Primary Completion Date

March 17, 2019

Study Completion Date

March 17, 2019

Conditions
Obesity
Interventions
DRUG

JNJ-64565111

JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.

Trial Locations (1)

85283

Celerion, Tempe

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03586843 - A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose | Biotech Hunter | Biotech Hunter